Back to news

Pivotal to collaborate with Checkpoint Therapeutics on a study in patients with cutaneous squamous cell carcinoma

  • Global trial has recently expanded to Western Europe with the first European sites now initiated
  • Collaboration will enable patients in Europe to access PD-L1 inhibitor to treat cSCC not amenable for local treatments

 

 

Forward‐Looking Statements

 

 

MEDIA CONTACT

Ms. Natalia Farr

natalia.farr@pivotalcr.com